Ozempic Availability 2024: Market Status & Treatment Options

Last reviewed: May 22, 2026

Last updated: May 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, Ozempic is not being taken off the market—it remains FDA-approved and manufactured by Novo Nordisk. However, intermittent supply constraints and high demand have created real access challenges since 2023, affecting patient availability and insurance coverage.

For patients exploring GLP-1 therapy, understanding current Ozempic availability matters because access delays can affect treatment timelines. PlexusDx focuses on precision-guided alternatives, including compounded semaglutide and tirzepatide, paired with genetic insights to support more personalized conversations with your provider.

Why Ozempic Availability Has Been Inconsistent

Ozempic shortages stem from unexpectedly high demand—driven by both diabetes management and off-label weight loss use—combined with manufacturing capacity constraints. Novo Nordisk has acknowledged these pressures and expanded production, but supply remains subject to market fluctuations.

Insurance coverage variability has worsened access. Many plans restrict Ozempic to type 2 diabetes only, leaving weight management patients without coverage. This creates a gap where patients either wait for supply or explore alternative GLP-1 formulations through compounding or other licensed channels.

GLP-1 Market Landscape: Branded vs. Compounded Options

The GLP-1 market now includes multiple pathways: branded injectables (Ozempic, Mounjaro, Saxenda), oral options (Rybelsus), and licensed 503A compounded formulations. Each has distinct regulatory status, cost, and access profiles. Understanding these differences helps patients and providers select the right approach for their situation.

Option	Active Ingredient	Typical Cost Range	Access Considerations
Ozempic (branded)	Semaglutide injection	Insurance-dependent; $900–$1,400/mo uninsured	Supply variability; insurance restrictions common
Compounded semaglutide	Semaglutide injection	$149/mo	Licensed 503A pharmacies; no insurance needed
Mounjaro (branded)	Tirzepatide injection	Insurance-dependent; $1,000+/mo uninsured	More stable supply; higher cost barrier
Compounded tirzepatide	Tirzepatide injection	$249/mo	Licensed 503A pharmacies; rapid access

How Genetic Factors Shape GLP-1 Response Conversations

Individual genetic variants in GLP-1 receptor pathways, FTO signaling, and melanocortin-4 pathways influence how patients metabolize and respond to GLP-1 therapy. These predispositions can support more informed conversations with providers about which formulation or dose may align with your biology.

The Precision Peptide Genetic Test screens for key variants—including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—that may help provide context for treatment personalization. This test does not predict exact medication response but can support a more targeted provider discussion when evaluating Ozempic alternatives.

What Patients Should Consider When Evaluating Alternatives

Before switching from Ozempic or exploring new options, work with your provider to clarify your treatment goal (diabetes, weight management, or both), current health status, and any side effect history. Supply availability should inform timing, not drive the clinical decision alone.

Compounded GLP-1 formulations from licensed 503A pharmacies offer faster access and lower out-of-pocket costs but require provider oversight just as branded options do. Your provider should remain involved in dose escalation, monitoring, and safety assessment regardless of formulation source.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context for GLP-1 treatment personalization by revealing predispositions in key peptide signaling pathways. When Ozempic availability is delayed or cost-prohibitive, understanding your genetic profile can support a more informed conversation with your provider about compounded semaglutide or tirzepatide alternatives.

The Precision Peptide Genetic Test screens variants associated with GLP-1 receptor sensitivity, metabolic rate, and appetite regulation. This test does not predict exact medication response or guarantee outcomes, but it can help identify which formulation or dosing strategy may align better with your biological pathway profile.

If Ozempic access is limiting your treatment timeline, combining genetic insights with a provider discussion about compounded alternatives allows for more personalized decision-making. PlexusDx supports this conversation by offering genetic testing at $99 (as an add-on) or $298 (standalone) to clarify pathway-level predispositions before starting or switching therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.